Fibrous dysplasia in cardio‐facio‐cutaneous syndrome: A case report and review of literature

Cardio‐facio‐cutaneous (CFC) syndrome (OMIM #:115150, 615278, 615279, 615280) is a rare genetic condition caused by variants in the RAS/mitogen‐activated protein kinase (MAPK) signal transduction pathway. Up to 75% of cases are caused by mutations in the BRAF gene, whereas KRAS gene mutation has onl...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of medical genetics. Part A Vol. 188; no. 9; pp. 2732 - 2737
Main Authors Dong, Xiaoao, Png, Nicholas C. Y., Fortier, Marielle V., Lim, Jiin Ying, Wong, Kenneth P. L., Choo, Jonathan T. L., Tan, Ene Choo, Jamuar, Saumya Shekhar
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.09.2022
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cardio‐facio‐cutaneous (CFC) syndrome (OMIM #:115150, 615278, 615279, 615280) is a rare genetic condition caused by variants in the RAS/mitogen‐activated protein kinase (MAPK) signal transduction pathway. Up to 75% of cases are caused by mutations in the BRAF gene, whereas KRAS gene mutation has only been reported in <2% of cases. CFC syndrome is characterized by cardiac abnormalities, distinctive craniofacial dysmorphism, and various cutaneous abnormalities. Musculoskeletal and orthopedic manifestations are also prevalent in patients with CFC syndrome, among which the most common are skeletal deformities and joint laxities. Dysplastic bone disorders, on the other hand, have not been reported in CFC syndrome before. We report on a case of symmetrical polyostotic fibrous dysplasia (FD) in a patient with CFC syndrome with the KRAS(NM_004985.5):c.57G>C; p.Leu19Phe variant. The FDs were incidentally picked up, and patient was conservatively managed and remained asymptomatic on follow‐up. The same variant was reported previously in a patient with Oculoectodermal Syndrome (OES), who developed polyostotic non‐ossifying fibroma (NOF). This case explores FD as a possible new clinical feature of CFC syndrome, and when linked to the historical case of OES, explores whether the KRAS(NM_004985.5):c.57G>C; p.Leu19Phe mutation may potentially contribute to the development of dysplastic bone lesions in patients with this particular mutation.
Bibliography:Funding information
National Medical Research Council, Grant/Award Numbers: NMRC/CG/M003/2017, NMRC/CSAINV21jun‐0003
ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Review-3
content type line 23
ObjectType-Article-4
ObjectType-Report-1
ISSN:1552-4825
1552-4833
DOI:10.1002/ajmg.a.62879